Pharmaceuticals, Biotechnology and Life Sciences
A T Cell Receptor (TCR) biotechnology specialist Immunocore Limited, has entered into a new partnership with Genentech, a member of…
Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
Illumina will acquire Pacific Biosciences for $1.2 billion, it was revealed on Friday, after the agreement had been approved by the board of directors of Illumina and Pacific Biosciences.
$ILMN $PACB
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM
Advanced Stem Cell Training Network (ASCTN), a European research consortium , has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson´s, Huntington´s and Demyelination disease – which are caused by acute or progressive loss of cells in the brain, said Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, in which the company is a partner organisation
Omya, a producer of industrial minerals informed Monday about a price increase of 7 – 9% for its Calcium Carbonate products in the US and Canada, from the start of the next year.
@n4pharma with MedImmune UK, has been studying the level of immune response Nuvec can deliver when combined with a target antigen in a study using messenger RNA (mRNA) and plasmid DNA (pDNA) encoded with the standard test antigen Ovalbumin (OVA).
Spanish contract development and manufacturing organisation (CDMO) @Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma.